Lead-time bias can be avoided by screening for antibodies in SCLC patients without PNDs, previous such studies have focussed on a narrow range of antibodies, for example in a series of 27 non-PND HuD-Ab positive patients median survival appeared longer for patients with HuD-Abs than their negative counterparts [16]. The gene discussed is ELAVL4; the disease is small cell lung carcinoma.